Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 3/20 | 0.38 |
| ▸ | HPGDS | O60760 | 2/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.36 |
| ▸ | CCNK | O75909 | 1/20 | 0.36 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18289981 | 1.00 | HCAR1 (0.41) | HCAR1FPR2HTR6BTKHPGDS | |
| SCHEMBL30111817 | 1.00 | HCAR1 (0.41) | HCAR1FPR2HTR6BTKHPGDS | |
| SCHEMBL18818279 | 1.00 | HCAR1 (0.41) | HCAR1FPR2HTR6BTKHPGDS | |
| SCHEMBL18818280 | 1.00 | HCAR1 (0.41) | HCAR1FPR2HTR6BTKHPGDS | |
| SCHEMBL28490359 | 0.88 | BTK (0.35) | BTKJAK2JAK1 | |
| SCHEMBL18285529 | 0.88 | BTK (0.35) | BTKJAK2JAK1 | |
| SCHEMBL18285525 | 0.88 | BTK (0.35) | BTKJAK2JAK1 | |
| SCHEMBL18285530 | 0.88 | BTK (0.35) | BTKJAK2JAK1 | |
| SCHEMBL24590580 | 0.87 | JAK1 (0.33) | HCAR1FPR2USP30JAK1GPR119 | |
| SCHEMBL29737066 | 0.87 | JAK1 (0.33) | HCAR1FPR2USP30JAK1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3912979-B1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20250197402-A1 | Tyrosine Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2025-06-19 | — | — | US | disclosed |
| US-20230151012-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2023-05-18 | — | — | US | disclosed |
| EP-4112618-A1 | TYROSINE KINASE INHIBITORS | Principia Biopharma Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| EP-3912979-A1 | TYROSINE KINASE INHIBITORS | Principia Biopharma Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| US-20210171526-A1 | Tyrosine Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2021-06-10 | — | — | US | disclosed |
| US-20180162861-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2018-06-14 | — | — | US | disclosed |
| EP-3303334-A1 | TYROSINE KINASE INHIBITORS | Principia Biopharma Inc. (US) | 2018-04-11 | — | — | EP | disclosed |
| US-9688676-B2 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170129890-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2017-05-11 | — | — | US | disclosed |
| WO-2016196840-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171526-A1 | Tyrosine Kinase Inhibitors | BTK, LYN, SYK | HCAR1 4128/4885FPR2 1211/4885HTR6 4214/4885 |
| US-20180162861-A1 | TYROSINE KINASE INHIBITORS | BTK, LYN, SYK | HCAR1 4128/4885FPR2 1211/4885HTR6 4214/4885 |
| US-20170129890-A1 | TYROSINE KINASE INHIBITORS | BTK, LYN, SYK | HCAR1 4128/4885FPR2 1211/4885HTR6 4214/4885 |
| US-20230151012-A1 | TYROSINE KINASE INHIBITORS | BTK, LYN, SYK | HCAR1 4128/4885FPR2 1211/4885HTR6 4214/4885 |
| US-20250197402-A1 | Tyrosine Kinase Inhibitors | BTK, LYN, SYK | HCAR1 4128/4885FPR2 1211/4885HTR6 4214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.